share_log

醫渡科技：截至2024年9月30日止六個月的中期業績公告

YIDU TECH: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024

HKEX ·  Nov 21 17:04

Summary by Moomoo AI

截至2024年9月30日止六個月，醫渡科技的收入為人民幣329.4百萬元，同比下降7.6%。毛利為人民幣117.4百萬元，同比下降13.8%。經營虧損縮減至人民幣54.3百萬元，同比減少30.7%。期間虧損縮減至人民幣56.4百萬元，同比減少29.2%。董事會不建議派發中期股息。\\n管理層指出，收入下降主要受外部市場環境及產品組合變化影響。然而，內部運營效率提升及業務板塊間的協同效應增強，導致虧損縮減。公司在AI技術和醫療領域的深厚積累，推動了技術落地和標準化建設，進一步推動醫療行業的智能轉型。公司現金儲備充足，現金及現金等價物、定期存款等合計為人民幣3,188.7百萬元。\\n展望未來，醫渡科技將繼續優化醫療垂直領域的大語言模型，提升AI醫療大腦YiduCore的功能，推動自研大模型在各個醫療生態場景的落地。公司將加強核心技術投入，深化疾病研究與應用，並通過戰略合作夥伴關係、投資和收購豐富生態系統。
截至2024年9月30日止六個月，醫渡科技的收入為人民幣329.4百萬元，同比下降7.6%。毛利為人民幣117.4百萬元，同比下降13.8%。經營虧損縮減至人民幣54.3百萬元，同比減少30.7%。期間虧損縮減至人民幣56.4百萬元，同比減少29.2%。董事會不建議派發中期股息。\\n管理層指出，收入下降主要受外部市場環境及產品組合變化影響。然而，內部運營效率提升及業務板塊間的協同效應增強，導致虧損縮減。公司在AI技術和醫療領域的深厚積累，推動了技術落地和標準化建設，進一步推動醫療行業的智能轉型。公司現金儲備充足，現金及現金等價物、定期存款等合計為人民幣3,188.7百萬元。\\n展望未來，醫渡科技將繼續優化醫療垂直領域的大語言模型，提升AI醫療大腦YiduCore的功能，推動自研大模型在各個醫療生態場景的落地。公司將加強核心技術投入，深化疾病研究與應用，並通過戰略合作夥伴關係、投資和收購豐富生態系統。
As of the six months ended September 30, 2024, Yidu Technology's revenue was RMB 329.4 million, a decrease of 7.6% year-on-year. Gross profit was RMB 117.4 million, a decrease of 13.8% year-on-year. Operating loss reduced to RMB 54.3 million, a decrease of 30.7% year-on-year. Net loss reduced to RMB 56.4 million, a decrease of 29.2% year-on-year. The board of directors does not recommend the distribution of interim dividends. Management pointed out that the decline in revenue was mainly due to the external market environment and changes in product portfolio. However, the improvement in internal operational efficiency and the enhanced synergy between business sectors led to a reduction in losses. The company's deep accumulation in AI technology and medical field has...Show More
As of the six months ended September 30, 2024, Yidu Technology's revenue was RMB 329.4 million, a decrease of 7.6% year-on-year. Gross profit was RMB 117.4 million, a decrease of 13.8% year-on-year. Operating loss reduced to RMB 54.3 million, a decrease of 30.7% year-on-year. Net loss reduced to RMB 56.4 million, a decrease of 29.2% year-on-year. The board of directors does not recommend the distribution of interim dividends. Management pointed out that the decline in revenue was mainly due to the external market environment and changes in product portfolio. However, the improvement in internal operational efficiency and the enhanced synergy between business sectors led to a reduction in losses. The company's deep accumulation in AI technology and medical field has promoted the implementation of technology and standardization construction, further driving the intelligent transformation of the medical industry. The company has sufficient cash reserves, with total cash and cash equivalents, time deposits, etc., amounting to RMB 3188.7 million. Looking ahead, Yidu Technology will continue to optimize the large language models in the medical vertical field, enhance the functionality of the AI medical brain YiduCore, promote the application of self-developed large models in various medical ecological scenarios. The company will strengthen core technology investment, deepen disease research and application, and enrich the ecosystem through strategic partnerships, investments, and acquisitions.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated